Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Curti

Showing results (1-10 of 136) with videos related to

Pageof 14
Sort By:
British Journal of Haematology|January 22, 2020
Good news for acute myeloid leukaemia patients from the stroll niche?Marilena Ciciarello, Antonio Curti
Immunotherapy|December 18, 2013
Immunotherapy in acute myeloid leukemiaMario Arpinati, Antonio Curti
Frontiers in Oncology|May 3, 2021
Editorial: The Biological Landscape of Immunotherapy in AMLAlessandro Isidori, Naval Daver, Antonio Curti
Seminars in Hematology|October 4, 2025
The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategiesMarion Subklewe, Sergio Rutella, Antonio Curti
Blood|October 23, 2008
More ADO about IDO: GVHDAntonio Curti, Sara Trabanelli, Roberto M Lemoli
Experimental Hematology|November 10, 2016
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemiaRoberto M Lemoli, Sarah Parisi, Antonio Curti
Blood|October 24, 2002
Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphomaAntonio Curti, Mariella Parenza, Mario P Colombo
Frontiers in Immunology|November 4, 2015
Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive ImmunotherapyLoredana Ruggeri, Sarah Parisi, Elena Urbani, et al.
Frontiers in Oncology|October 16, 2019
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaFederica Loscocco, Giuseppe Visani, Sara Galimberti, et al.
Current Opinion in Pharmacology|November 7, 2025
CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectivesFederico Zingarelli, Jacopo Nanni, Gianluca Cristiano, et al.
Pageof 14

Showing results (1-10 of 136) with videos related to

Sort By:
Pageof 14
British Journal of Haematology|January 22, 2020
Good news for acute myeloid leukaemia patients from the stroll niche?Marilena Ciciarello, Antonio Curti
Immunotherapy|December 18, 2013
Immunotherapy in acute myeloid leukemiaMario Arpinati, Antonio Curti
Frontiers in Oncology|May 3, 2021
Editorial: The Biological Landscape of Immunotherapy in AMLAlessandro Isidori, Naval Daver, Antonio Curti
Seminars in Hematology|October 4, 2025
The immunotherapy landscape in AML: Defining knowledge gaps toward rational combinatorial strategiesMarion Subklewe, Sergio Rutella, Antonio Curti
Blood|October 23, 2008
More ADO about IDO: GVHDAntonio Curti, Sara Trabanelli, Roberto M Lemoli
Experimental Hematology|November 10, 2016
Novel strategies of adoptive immunotherapy: How natural killer cells may change the treatment of elderly patients with acute myeloblastic leukemiaRoberto M Lemoli, Sarah Parisi, Antonio Curti
Blood|October 24, 2002
Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphomaAntonio Curti, Mariella Parenza, Mario P Colombo
Frontiers in Immunology|November 4, 2015
Alloreactive Natural Killer Cells for the Treatment of Acute Myeloid Leukemia: From Stem Cell Transplantation to Adoptive ImmunotherapyLoredana Ruggeri, Sarah Parisi, Elena Urbani, et al.
Frontiers in Oncology|October 16, 2019
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaFederica Loscocco, Giuseppe Visani, Sara Galimberti, et al.
Current Opinion in Pharmacology|November 7, 2025
CRISPR-Cas9 in acute myeloid leukaemia: Current state-of-art and future perspectivesFederico Zingarelli, Jacopo Nanni, Gianluca Cristiano, et al.
Pageof 14